Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Company and personnel
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
04 Jun 2021
KOL Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment
25 May 2021
GenSight Biologics Announces Nature Medicine Case Report Showing Visual Recovery after GS030 Optogenetic Treatment
19 May 2021
GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch
19 May 2021 - 21 May 2021
Advanced Therapies – Virtual
17 May 2021
GenSight Biologics Appoints Françoise de Craecker to its Board of Directors
14 May 2021
GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19
03 May 2021
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
29 Apr 2021
Annual General Meeting 2021
20 April 2021
GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update
08 April 2021
GenSight Biologics Announces the Filing of its 2020 Universal Registration Document
View previous 9 articles
1
…
3
4
5
6
7
8
9
10
11
12
13
…
18
View next 9 articles
Go back to the page of the page